Syros Pharmaceuticals, Inc. (SYRS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 5.07 |
| Open | 5.20 |
| Bid | 5.06 x 300 |
| Ask | 5.13 x 400 |
| Day's range | 4.92 - 5.15 |
| 52-week range | 2.09 - 8.17 |
| Volume | |
| Avg. volume | 212,500 |
| Market cap | 136.314M |
| Beta (5Y monthly) | 1.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.81 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.25 |
ZacksThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksSyros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
ZacksSyros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
© 2024 Yahoo. All rights reserved.